Skip to content

Announcing new clinics across Norway

Expanding the availability of Lenire to people living with tinnitus is one of our core goals, so we are delighted to announce that our partner clinic in Norway, HØR AS, is opening two new clinics, HØR Sandefjord and HØR Trondheim. This greatly increases the availability of Lenire for people living with tinnitus in Norway.

The team at the launch of HØR Sandefjord
Opening day at the clinic

Tinnitus is thought to affect 10-15% of the adult population globally1 which could mean up to 650,000 Norwegians are living with the condition. Lenire is an evidence-based medical device which can provide sustainable relief from the symptoms of tinnitus. HØR AS is Norway’s largest private provider of hearing and tinnitus care.

HØR’s specialist audiology team has licence from Neuromod to provide Lenire for the treatment of tinnitus to suitable patients in their chain of private clinics throughout NorwayHØR’s flagship clinic is at Ullevål Stadion, with an additional inhouse clinic at Aleris Frogner and now two new clinics in Trondheim and Sandefjord.

The expansion comes following the publication of the second large-scale clinical trial of Lenire in Nature – Scientific Reports. The results of this trial showed greater average improvement in tinnitus symptoms than the first clinical trial due to optimised treatment plans for participants2. 95% of treatment-compliant participants reported an improvement in their tinnitus symptoms2,as measured by THI3.

Norway is the latest country that Lenire is available in following significant expansion of the device’s availability throughout Europe, including the UK, Spain, Switzerland, and Austria, and with further launches planned in Hungary, Poland and Sweden in the coming months.

References:

  1. Baguely et al., Tinnitus, The Lancet (2013), https://www.sciencedirect.com/science/article/pii/S0140673613601427
  2. Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, https://doi.org/10.1038/s41598-022-13875-x (2022)
  3. THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone’s day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person’s THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them.

Subscribe to our Newsletter

Our dedicated newsletter for healthcare professionals will keep you up to date with the Lenire® treatment and research.

In order to subscribe you to our newsletter, we require your consent to send marketing communications to you. Please tick the box below to consent to:

You can unsubscribe from these communications at any time. For more information view our privacy policy.

By clicking subscribe, you consent to allow Neuromod Medical to store and process the personal information submitted above to provide you with the content requested.